NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. (“Lev”) (OTCBB: LEVP) today announced financial results for the second quarter ended June 30, 2007.
Highlights and Current Developments:
* Submitted Biologics License Application for Cinryze™ in July
* Completed Phase III Prophylaxis trial for the treatment of HAE
